SCHEMBL14607252

SCHEMBL14607252

Bc1cnn2c(NCc3cccnc3)cc(C3CCCN(S(=O)(=O)c4cccc(OC(F)(F)F)c4)C3)nc12

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 4/20 0.48
▸ LMNA P02545 4/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ HTT P42858 1/20 0.44
▸ CHEK1 O14757 1/20 0.42
▸ NAMPT P43490 4/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ KCNN3 Q9UGI6 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ USP2 O75604 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13120616 0.92 GSK3B (0.59) GSK3B
SCHEMBL14545996 0.92 GSK3B (0.48) GSK3BLMNASMN1; SMN2HTTCHEK1
SCHEMBL14307160 0.92 GSK3B (0.51) GSK3BLMNASMN1; SMN2HTTCHEK1
SCHEMBL12954478 0.91 GSK3B (0.50) GSK3BLMNASMN1; SMN2CHEK1NAMPT
SCHEMBL14418706 0.89 GSK3B (0.52) GSK3BLMNASMN1; SMN2CHEK1NAMPT
SCHEMBL14581372 0.88 GSK3B (0.52) GSK3BLMNASMN1; SMN2CHEK1NAMPT
SCHEMBL14043358 0.86 GSK3B (0.53) GSK3BLMNASMN1; SMN2CHEK1NAMPT
SCHEMBL14301590 0.86 GSK3B (0.55) GSK3BLMNASMN1; SMN2CHEK1NAMPT
SCHEMBL12954428 0.85 GSK3B (0.61) GSK3BLMNASMN1; SMN2HTTMEN1
SCHEMBL12953926 0.85 GSK3B (0.52) GSK3BLMNASMN1; SMN2HTTCHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070054906-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2007-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054906-A1 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors CDK2, CDK1, CDKN1A GSK3B 695/4885LMNA 1706/4885SMN1; SMN2 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback